In its latest Form 13F filing with the SEC, AlphaQuest LLC disclosed a 1,038% increase in its holding of ResMed Inc. shares during the third quarter. The firm added 14,013 shares to bring its total stake to 15,363 shares, representing a position valued at approximately $4.2 million at quarter end. This move marks one of the largest single-quarter increases in ResMed stock by any institutional investor over the past two years.

Several smaller funds also adjusted their ResMed positions in the same period. SJS Investment Consulting raised its stake by 1,433%, acquiring 86 additional shares to reach a total of 92. Harbour Investments increased its holdings by 264%, ending the quarter with 244 shares. Meanwhile, WFA of San Diego, GoalVest Advisory and Root Financial Partners initiated new positions, each investing in the range of $26,000 to $64,000. Collectively, hedge funds and institutions now own 54.98% of ResMed’s outstanding shares.

ResMed’s fiscal second quarter results, reported in late January, featured revenue of $1.42 billion—up 11% year-over-year—and non-GAAP gross margin expansion of 310 basis points to 62.3%. The company delivered non-GAAP EPS of $2.81, a 16% increase from the prior year, driven by strong device demand and operational efficiencies. Operating cash flow reached $340 million, supporting $88 million in dividends and $175 million in share repurchases during the quarter.

Following the earnings release, KeyCorp raised its price objective slightly and maintained an overweight rating, while other firms such as Mizuho and Robert W. Baird trimmed targets but kept positive outlooks. Consensus among 15 analysts stands at a moderate buy, with an average target near the high-200s. On the insider front, Director Peter C. Farrell and CEO Michael J. Farrell sold a combined 10,011 shares in late 2025 and early 2026, reducing their positions by 2.91% and 1.68%, respectively, and collectively generating proceeds of around $2.5 million.